Related Experiment Video
Updated: Apr 22, 2026
Retroviral Transduction of T-cell Receptors in Mouse T-cells
Published on: October 22, 2010
Different immunological mechanisms govern protection from experimental stroke in young and older mice with
Abby L Dotson1, Wenbin Zhu2, Nicole Libal2
1Neuroimmunology Research, VA Medical Center Portland, OR, USA ; Department of Neurology, Oregon Health and Science University Portland, OR, USA.
Abstract:
Stroke is a leading cause of death and disability in the United States. The lack of clinical success in stroke therapies can be attributed, in part, to inadequate basic research on aging rodents. The current study demonstrates that recombinant TCR ligand therapy uses different immunological mechanisms to protect young and older mice from experimental stroke. In young mice, RTL1000 therapy inhibited splenocyte efflux while reducing frequency of T cells and macrophages in the spleen. Older mice treated with RTL1000 exhibited a significant reduction in inflammatory cells in the brain and inhibition of splenic atrophy. Our data suggest age specific differences in immune response to stroke that allow unique targeting of stroke immunotherapies.
Insights
Recombinant TCR ligand therapy (RTL1000) offers stroke protection through distinct immune responses in young and aging mice. This research highlights age-specific immune differences crucial for developing targeted stroke immunotherapies.
Area of Science:
- Immunology
- Neuroscience
- Gerontology
Background:
- Stroke is a major cause of death and disability.
- Limited clinical success in stroke therapies may stem from insufficient research in aging animal models.
- Understanding age-related immune responses is vital for effective stroke treatment.
Purpose of the Study:
- To investigate the age-specific immunological mechanisms of recombinant TCR ligand therapy (RTL1000) in experimental stroke.
- To compare the effects of RTL1000 on immune responses in young versus older mice.
- To identify potential age-specific targets for stroke immunotherapies.
Main Methods:
- Experimental stroke model in young and older mice.
- Administration of recombinant TCR ligand therapy (RTL1000).
- Analysis of splenocyte efflux, T cell and macrophage frequencies, splenic atrophy, and brain inflammatory cell infiltration.
Main Results:
- In young mice, RTL1000 inhibited splenocyte efflux and reduced T cells and macrophages in the spleen.
- In older mice, RTL1000 significantly reduced inflammatory cells in the brain and inhibited splenic atrophy.
- Distinct immunological pathways were observed in young and older mice treated with RTL1000.
Conclusions:
- Immune responses to stroke exhibit age-specific differences.
- RTL1000 employs distinct mechanisms to protect young and aging mice from stroke.
- These findings suggest opportunities for age-targeted stroke immunotherapies.
More Related Videos
11:21Streamlined Single Cell TCR Isolation and Generation of Retroviral Vectors for In Vitro and In Vivo Expression of Human TCRs
Published on: September 10, 2017
09:08Retroviral Transduction of Bone Marrow Progenitor Cells to Generate T-cell Receptor Retrogenic Mice
Published on: July 11, 2016